Centinel Spine Holdco, a medical device company developing total disc replacement implants for the cervical and lumbar spine, has filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering. The Pennsylvania-based company is seeking to expand the public-market profile of its motion-preserving spinal implant platform, which is designed as an alternative to spinal fusion.

Total Disc Replacement Platform

Centinel Spine develops total disc replacement (TDR) implants for the cervical and lumbar spine. Its implants are designed to preserve motion in the spine rather than permanently joining vertebrae through spinal fusion.

The company’s prodisc platform includes four cervical systems and one lumbar system. The platform has received FDA approval for one- and two-level procedures in both regions of the spine.

The technology gives Centinel Spine exposure to the spinal implant market, particularly procedures where motion preservation is an alternative to fusion.

Manufacturing and Sales Network

Centinel Spine outsources manufacturing to Hammill Manufacturing, an Ohio-based manufacturer.

In the United States, the company sells its products through a dedicated sales team supported by more than 400 independent distributors. This distribution network provides Centinel Spine with an established channel for bringing its spinal implant products to healthcare providers.

Company Background

Centinel Spine Holdco was formed in 2008 through the merger of Raymedica and Surgicraft. The company is based in West Chester, Pennsylvania.

Centinel Spine generated approximately $157 million in revenue for the 12 months ended June 30, 2026, giving the company a substantial operating base ahead of its proposed public offering.

IPO and NYSE Listing Details

Centinel Spine plans to list its shares on the New York Stock Exchange under the symbol CNTL. The company has proposed raising up to $100 million, although no pricing terms have been disclosed.

Centinel Spine Holdco filed confidentially with the SEC on May 8, 2026.

Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity and BTIG are serving as joint bookrunners for the offering.

Market Context & Opportunities

Centinel Spine’s focus on total disc replacement positions the company within the broader spinal surgery and medical device market. Its prodisc platform combines cervical and lumbar applications, while FDA approvals covering one- and two-level procedures provide an established regulatory foundation for its products.

The company’s more than $150 million in trailing revenue and network of more than 400 independent U.S. distributors also give it an established commercial platform as it prepares for a potential NYSE listing.

Risks & Challenges

Centinel Spine operates in a specialized medical device market where product adoption, regulatory requirements and clinical outcomes can influence commercial performance. Its reliance on outsourced manufacturing also makes its manufacturing relationship an important component of its operating model.

The company has not yet disclosed pricing terms for the IPO, meaning the eventual valuation and amount of equity offered will be important factors for investors assessing the transaction.

Closing Paragraph

Centinel Spine Holdco is seeking to raise up to $100 million through an IPO on the NYSE, bringing its motion-preserving spinal implant business toward the public markets. With its FDA-approved prodisc platform, more than $157 million in trailing revenue and a U.S. distribution network exceeding 400 independent distributors, the company enters the IPO pipeline with an established commercial and product base.